Loxo Oncology Profile

104.97
USD 0.17  0.16%
90.75
100%
104.97
101.70
51%
107.99

Sale by Aisling Capital Iii Lp of 250000 shares of Loxo Oncology

Loxo Oncology Inc insider trading alert for sale of common stock by Aisling Capital Iii Lp, the corporate stakeholder, on February 5, 2018. This event was filed by Loxo Oncology Inc with SEC on 2017-12-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Loxo Oncology Summary

Loxo Oncology Inc (LOXO) is traded on NASDAQ General Markets in USA. It is located in CONNECTICUT, U.S.A and employs 47 people. Loxo Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 3.02 B. Loxo Oncology Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 29.94 M outstanding shares of which 3.38 M shares are now shorted by private and institutional investors with about 6.6 trading days to cover. Loxo Oncology currently holds about 371.67 M in cash with (128.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.41.
Check Loxo Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares4.5 M378 M
Aisling Capital LlcCommon Shares3.4 M289.5 M
View Loxo Oncology Diagnostics

Selected Loxo Oncology Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Loxo Oncology Against Markets

Risk Adjusted
Performance Score (0 to 100)
8 
Chance of
Financial Distress (0 to 100%)
< 41% 
Equity ratings for Loxo Oncology Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 47 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameLoxo Oncology Inc
President CEO, DirectorJoshua BilenkerAll Leadership
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationCONNECTICUT, U.S.A
Business Address281 Tresser Boulevard
ExchangeNASDAQ General Markets
CIK Number01581720.0
CUSIP548862101
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.loxooncology.com
Contact Number203 653 3880
CurrencyUSD - US Dollar

Recommendations

Loxo Oncology Analyst Recommendations
Target PriceAdvice# of Analysts
50.33Strong Buy3Odds
Loxo Oncology Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Loxo Oncology Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Loxo Oncology Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.86March 21, 2017
Loxo Oncology Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Loxo Oncology Corporate Directors
James Barrett Independent Director, MBA
Timothy Mayleben Independent Director, MBA
Avraham Naider Independent Director